A Varian Portal Dosimetry system was compared to an isocentrically mounted MapCHECK 2 diode array for volumetric modulated arc therapy (VMAT) QA. A Varian TrueBeam STx with an aS-1000 digital imaging panel was used to acquire VMAT QA images for 13 plans using four photon energies (6, 8, 10 and 15 MV). The EPID-based QA images were compared to the Portal Dose Image Prediction calculated in the Varian Eclipse treatment planning system (TPS). An isocentrically mounted Sun Nuclear MapCHECK 2 diode array with 5 cm water-equivalent buildup was also used for the VMAT QAs and the measurements were compared to a composite dose plane from the Eclipse TPS. A γtest was implemented in the Sun Nuclear Patient software with 10% threshold and absolute comparison at 1%/1 mm (dose difference/distance-to-agreement), 2%/2 mm, and 3%/3 mm criteria for both QA methods. The two-tailed paired Student's t-test was employed to analyze the statistical significance at 95% confidence level. The average γpassing rates were greater than 95% at 3%/3 mm using both methods for all four energies. The differences in the average passing rates between the two methods were within 1.7% and 1.6% of each other when analyzed at 2%/2 mm and 3%/3 mm, respectively. The EPID passing rates were somewhat better than the MapCHECK 2 when analyzed at 1%/1 mm; the difference was lower for 8 MV and 10 MV. However, the differences were not statistically significant for all criteria and energies (p-values ＞0.05). The EPID-based QA showed large off-axis over-response and dependence of γpassing rate on energy, while the MapCHECK 2 was susceptible to the MLC tongue-and-groove effect. The two fluence-based QA techniques can be an alternative tool of VMAT QA to each other, if the limitations of each QA method (mechanical sag, detector response, and detector alignment) are carefully considered.
Introduction
Volumetric modulated arc therapy (VMAT) can deliver highly conformal dose distributions with better monitor unit (MU) efficiency and shorter treatment time. However, a patient-specific VMAT quality assurance (QA) is more challenging than conventional intensity modulated radiation therapy (IMRT) due to increased complexity such as variations in gantry speed and dose rate with complicated leaf sequencing.
Electronic portal imaging device (EPID) is attractive for the IMRT and VMAT QA using portal imaging and dosimetry due to high resolution of imaging and simple set-up of the detector. Bakhiari et al. 1) used a 38% isointensity line of cine EPID images to verify multileaf collimator (MLC) leaf positions during VMAT delivery. Sharma et al. 2) tested the EPID portal dosimetry for IMRT QA using 181 intensity modulated fields that was compared to a two-dimensional (2D) ion chamber array (MatriXX, IBA, Louvain-la-Neuve, Belgium), and concluded that both fluence verification methods produced comparable QA results. Clemente et al. 3) reported that the portal dosimetry was a useful QA tool for dynamic and static IMRT delivery. Applicability and limitations of the portal dosimetry for VMAT QA have been also investigated. [4] [5] [6] [7] [8] [9] [10] Baily et al. 4) 
Materials and Methods

VMAT plans
Varian VMAT treatment plans for 13 patients involving different disease sites (two brains, one chest, three head and necks (H&Ns), one lung, one pancreas, two prostates, one rectum, and two stomachs) were retrospectively selected in this study. For the same patient, the VMAT plans were re-gen- Inter-energy variations using the same QA device were also examined.
Results
The average γpassing rates were greater than 95% at 3%/3 mm criteria using both QA methods for all four energies as shown in Table 1 , which was clinically acceptable according to Stock et al. 18) The γpassing rates of EPID-based QA were better than those of MapCHECK 2 QA for all four energies when analyzed at 1%/1 mm (3.1% (10 MV) to 9.4% (6 MV) higher). However, the differences were not statistically significant (p＞0.05) for all criteria and energies as shown in Table 1 .
Dependence of γpassing rate on field size was observed in the EPID-based QA as shown in Fig. 2 . One of the stomach patients showed extremely low passing rates (from 79.7% for 8 MV to 89.0% for 6 MV at 3%/3 mm), whose equivalentsquare field size by jaw setting (21.7 cm) was much larger than the other plans. Relatively low passing rates (less than 95%) for plans with small field size (less than 10 cm) were also observed for two brain patients at 8 MV and 10 MV (the same trend was observed at 1%/1 mm and 2%/2 mm). The
MapCHECK 2 QA did not show any dependence of γpassing rate on field size; however, low passing rates for a H&N plan (less than 95% at 3%/3 mm) using four energies were found.
None of the plans had the γpassing rates of less than 95% at 3%/3 mm using both QA methods.
The MapCHECK 2 QA did not show any statistically significant difference in γpassing rate using different energies at 3%/3 mm as shown in Table 2 . However, the 6 MV EPIDbased QAs showed better γpassing rates, while the 8 MV EPID-based QAs presented significantly lower γpassing rates than the other energies.
Discussion and Conclusions
The two QA methods based on portal dosimetry and Map-CHECK 2 were effective tools for VMAT QA and produced clinically acceptable γpassing rates for most of cases. However, each QA method had several statistical outliers whose passing rates were out of tolerance level. This originated from various contributing factors including mechanical sag and detector response.
Both QA measurements are affected by mechanical sag of detectors depending on gantry angle. Shifts in the center of the EPID images can be up to 5 mm reported by Bakhtiari et al. 1) This sag can be detected and corrected using two tungsten carbide ball bearings embedded in a 2 mm thick sold water slab detected by cine EPID imaging for arc delivery proposed by Rowshanfarzad et al. 10) Our machine has much less shifts in both cross-plane and in-plane profiles (up to 0.9 mm) and they
were not further corrected in this study. The MapCHECK 2 on IMF has similar shifts by up to 2.6 mm for our system and it can be simulated by splitting beam angles for dose calculation in TPS. 19) Jin et al. 20) showed that the correction of the shift (∼1.0 mm) would not make a statistically significant difference even if the γpassing rate would slightly improve. Table 2 shows the γpassing rate using different energies did not consistently have statistical significance (or insignificance). First, it should be noted that the plans using four different energies for the same patient did not have the same leaf modulation and MUs due to different optimization using different energies even if the same objectives were used. Second, the QA results were a complex interplay of a variety of uncertainty sources such as mechanical accuracy including the sagging issue, dependence of detector on energy and dose rate, accuracy of commissioning a planning system (especially for the portal dosimetry), and intrinsic calibration and dosimetric uncertainty of detector. And thus a large variation in the γ passing rate was sometimes observed even though the same VMAT plan was delivered for the QA especially at 1%/1 mm criteria. Our portal dosimetry and MapCHECK 2 system showed a good agreement (less than 1.0% dosimetric error) between calculation and measurement in an acceptance test using static 10×10 cm 2 field for all four energies. However, due to complexity mentioned above, it was not an easy task to identify the exact reasons why there was no consistency in the γpassing rate in terms of energy. It requires a further in-depth study.
The low γpassing rate for large-field EPID-based QA in 
